Dr Ola Landgren has designed studies to define biological mechanisms of transformation from myeloma precursor disease to myeloma. He has developed (1) early interventional clinical trials for patients with high-risk smoldering myeloma to delay/prevent transformation; (2) modern intervention trials for newly diagnosed multiple myeloma patients; and (3) cell- and molecular -based strategies to define minimal residual disease (MRD) detection post-therapy with the aim to improve clinical outcomes.